Breaking News

API Manufacturing Facility Expansion

March 21, 2016

€30 million investment is largest in Fermion’s history

Fermion has unveiled plans for its plant in the south of Finland, Hanko, which will start operating new API manufacturing facilities including 76 m3 reactor space, incremental to Fermion’s current total reactor volume of 320 m3. With best-in-class automated systems, controlled material flows, isolators and smart infrastructure the new facilities can process not only standard but also potent APIs. There will be a reactor space of 25 m3 for OEB5 compounds (containment level down to 0,1 µg/m3) and the rest of the new capacity is equipped for compounds requiring a containment level of 1 - 10 µg/m3.

With the new, modern facilities Fermion will be prepared to meet tightening regulatory requirements and better positioned to support both current and new business.

“The expansion lifts Fermion to a new level in the global arena of API and especially HAPI manufacturing, improving Fermion’s capability to meet increasing demand,” said Arto Toivonen president, Fermion. “Fermion will continue to ensure high quality and reliable delivery of its products. The new unit alone will be able to produce 100 metric tons HPAPI per year increasing the total production capacity of Fermion to over 400 metric tons API/year. Fermion’s scale of HPAPI development and production will now be complete with capabilities from grams to tons.”

Fermion’s investment of €30 million in Hanko is the largest in the history of the company since 1970 and also turns a new page in the history of the Finnish pharmaceutical industry.

The current Hanko plant is Fermion’s largest production facility with an annual API capacity of approximately 300 metric tons. The Hanko plant supports the full scale of commercial API manufacturing, both generic and custom APIs. The plant consists of three operational units, two dedicated for intermediate production and the third, fully automated unit inaugurated in 2001 produces APIs. The plant is equipped with dryers and mills for API micronization and has a Buss loop reactor for hydrogenations as well as an on-site incinerator of VOC gases and a biological wastewater treatment facility.

The expansion project already has a building permit and the planning is underway. The actual construction will start in the summer of 2016 and the inauguration will be celebrated in Q2 2018. 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks